Xenobiotic-metabolizing polymorphic enzymes. An opportunity for individualized drug treatment;Le polymorphisme génétique des enzymes du métabolisme des médicaments. Une opportunité pour un traitement individualisé

Bulletin de l'Academie Nationale de Medecine

Volumn 190, Issue 1, 2006, Pages 55-73

  Lhermitte, Michel ^a   Allorge, Delphine ^b   Broly, Franck ^b   Launois, Bernard ^b  

^a UNIV LILLE   (France)

^b NONE

Author keywords

Cytochrome P450 enzym system; Methyltransferases; Pharmacogenetics

Indexed keywords

EID: 33745769055     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33353-9     Document Type: Review

References (35)

1. LAZAROU J., POMERANZ B., COREY P. - Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc., 1998, 279, 1200-5.
2. POUYANNE P., HARAMBURU F., IMBS J., BEGAUD B. - Admissions to hospital caused by adverse drugs reactions: cross sectional incidence study. Br. Med. J., 2000, 320, 1036.
3. BEUTLER E. - Study of glucose-6-phosphate deshydrogenase: history and molecular biology. Am. J. Hematol., 1993, 42, 53-8.
4. EVANS DAP., MANLEY KA., MCKUSICK VA. - Genetic control of isoniazid metabolism in man. Br. Med. J., 1960, 2, 485-91.
5. INGELMANN-SUNDBERG M., OSCARSON M., MCLELLAN R. - Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. TIPS, 1999, 20, 342-9.
6. DALY A. - Pharmacogenetics of the major polymorphic metabolising enzymes. Fundam. Clin. Pharmacol., 2003, 17, 27-41.
7. OSCARSON M. - Pharmacogenetics of drug metabolising enzymes: importance for personalised medecine. Clin. Chem. Lab. Med., 2003, 41, 573-80.
8. BERTZ RJ., GRAMMENAM GR. - Use of in vitro and in vivo data to estimate the likehood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 1997, 32, 210-258.
9. MEYER U. - Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics, 1991, 1, 66-7.
10. GAEDIGK A. - Interethnic differences of drug-metabolising enzymes. Int. J. Clin. Pharmacol. Ther., 2000, 38, 61-8.
11. ALLORGE D., LORIOT MA. - La pharmacogénétique ou la promesse d'une médecine personnalisée: variations du métabolisme et du transport des médicaments. Ann. Biol. Clin., 2004, 62, 500-511.
12. ZANGER U., RAIMUNDO S., EICHELBAUM M. - Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch. Pharmacol., 2004, 369, 133-40.
13. SCHAEFFELER E., SCHWAB M., EICHELBAUM M., ZANGER U. - CYP2D6 genotyping strategy based on gene copy number determination by Taqman real-time PCR. Human Mutat., 2003, 22, 476-85.
14. BROLY F., MAREZ D., SABBAGH N., LEGRAND M., MILLESCAMPS S., LOGUIDICE JM., et al. - An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics, 1995, 5, 373-84.
15. BERTILSSON L., DAHL M., DALEN P., AL-SHURBAJI A. - Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol., 2002, 53, 111-22.
16. STEIMER W., MULLER B., LEUCHT S., KISSLING W. - Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin. Chim. Acta, 2001, 308, 33-41.
17. HAMMER W., SJÖQVIST F. - Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci., 1967, 8, 1895-903.
18. JOHANSSON I., LUNDQVIST E., BERTILSSON L., DAHL ML., SJÖQVIST F., INGELMAN-SUNDBERG M. - Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA, 1993, 90, 11825-9.
19. BURKE MJ., PRESKORN SH. - Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin. Pharmacokinet., 1999, 37, 147-85.
20. CHEN S., CHOU WH., BLOUIN RA., MAO Z., HUMPHRIES LL., MEEK QC. et al. - The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: sreening costs and influence on clinical outcomes in psychiatry. Clin. Pharmacol. Ther., 1996, 60, 522-34.
21. KAWANISHI C., LUNDGREN S., AGREN H., BERTILSSON L. - Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of non response. A pilot study. Eur. J. Clin. Pharmacol., 2004, 59, 803-7.
22. KIRCHLEINER J., BROSEN K., DAHL M., GRAM LF., KASPER S., ROOTS I. et al. - CYP2D6 and CYP2C19 genotype-based deose recommendations for anti-depressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. 2001, 104, 173-692.
23. KRYNETSKI E., EVANS W. - Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003, 22, 7403-13.
24. MCLEOD H., LIN J., SCOOT E., PUI C., EVANS W. - Thiopurine methyltransferase activity in american white subjects and black subjects. Clin. Pharmacol. Ther., 1994, 55, 15-20.
25. EVANS WE., HON Y., BOMGAARS L., COUTRE S., HOLDSWORTH M., JANCO R. et al. - Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol., 2001, 19, 2293-301.
26. RELLING M., HANCOK M., RIVIERA G. et al. - Mercaptopurine therapy intolerance and heterozygoty at the thiopurine S-methyl-transferase gene locus. J. Natl. Cancer Inst., 1999, 91, 2001-8.
27. DERVIEUX T., MEDARD Y., BAUDOUIN V. et al. - Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recippients treated with azathioprine. Br. J. Clin. Pharmacol. 1999, 48, 793-800.
28. TITINEN H., MATTILA MJ., ERIKSSON AW. - Comparison of the isoniazid inactivation in Finns and Lapons. Ann. Med. Intern. Fenn., 1968, 57, 161-166.
29. SEIFART HI., PARKIN DP., BOTHA FJ., DONALD PR., VAN DER WATT BJ. - Population screening for isoniazid acetylator phenotype. Pharmaco-epidemiol. Drug Safety, 2001, 10, 127-134.
30. ELLARD JA. - Variations between individuals and populations in acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol., 1976, 19, 610.
31. EICHELBAUM M., KROEMER MK., MIKUS G. - Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol. Lett. Spec. 1992, 64-65, 115-122.
32. OHNO M., YAMAGUCHI I., YAMAMOTO I. et al. - Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicine-induced hepatotoxicity. Int. J. Tuberc. Lung Dis., 2000, 4, 256-261.
33. KINZIG-SCHIPPERS M., TOMALIK-SCHARTE D., JETTER A. et al. - Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother., 2005, 49, 1733-8.
34. HOFFMEYER S., BURK O., von RITCHER O. et al. - Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 2000, 97, 3473-8.
35. ANGLICHEAU D., VERSTUYFT C., LAURENT-PUIG T. et al. - Association of multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol., 2003, 14, 1889-96.